Status:
COMPLETED
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
Lead Sponsor:
University of Alexandria
Conditions:
Systemic Sclerosis
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
Although the aetiology of SSc-PAH remains elusive, vascular dysfunction seems to be the initial event and statins through their vasculoprotective effect might be of value in the treatment armamentariu...
Detailed Description
Background: Pulmonary arterial hypertension (PAH) is an acknowledged devastating complication of systemic sclerosis (SSc); difficult to manage with a poor prognosis. Although the aetiology of SSc-PAH...
Eligibility Criteria
Inclusion
- New York Heart Association (NYHA) class III
- A mean pulmonary artery pressure (mPAP) of \> 30mmHg at rest
Exclusion
- Smoking
- Diabetes mellitus
- Hypercholesterolemia
- Hypertension
- Cardiac insufficiency
- Coexisting hepatic and renal diseases
- Use of drugs known to interact with statins.
- Patients with severe interstitial lung fibrosis
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00984932
Start Date
September 1 2008
End Date
July 1 2009
Last Update
September 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, University of Alexandria
Alexandria, Alexandria Governorate, Egypt, 203